RESUMEN
Cervical cancer (CC) is the most common human gynecological malignancy worldwide. Recently, accumulating evidences revealed the critical functions of miRNAs in the occurrence and development of cervical cancer. In our study, we aimed to demonstrate the function of miR-214-3p in regulating cell metastasis in cervical cancer. We showed low expression of miR-214-3p in cervical cancer cells and demonstrated downregulation of miR-214-3p promoted cervical cancer metastasis. Furthermore, THBS2 was identified as a novel target of miR-214-3p in cervical cancer cells. miR-214-3p suppressed THBS2 expression by directly targeting 3'UTR of THBS2, resulting in the inhibition of cell viability, invasion and migration. Taken together, the results implied inhibited effects of miR-214-3p on cervical cancer and provided new insight into potential ways for cervical cancer diagnosis and treatment.
Asunto(s)
MicroARNs , Neoplasias del Cuello Uterino , Femenino , Humanos , Línea Celular Tumoral , Movimiento Celular , Proliferación Celular , Regulación hacia Abajo , Regulación Neoplásica de la Expresión Génica , MicroARNs/genética , MicroARNs/metabolismo , Neoplasias del Cuello Uterino/genética , Neoplasias del Cuello Uterino/patologíaRESUMEN
OBJECTIVE: To study the postpartum pelvic floor rehabilitation on the improvement of pelvic floor electrical physiological indexes and the prevention of female pelvic floor dysfunction in China. METHODS: A multicenter prospective randomized controlled study was carried out. From October 2011, postpartum women in five provinces were randomly assigned into treatment group and control group. The women in treatment group received electrical stimulation and biofeedback treatment. The women in control group performed pelvic floor muscle exercise at home. When 6 months and 12 months after delivery, comparing two groups of patients with pelvic floor electrical physiological indexes and pelvic organ prolapse quantitation measurements (POP-Q), to evaluate the effect of postpartum pelvic floor rehabilitation on the prevention of pelvic floor dysfunction. Pelvic floor impact questionnaire short form (PFIQ-7) and pelvic organ prolapse/incontinence sexual questionnaire-12 (PISQ-12) were used to evaluate the influence on quality of life and sexual life. RESULTS: Until June 2013, 324 women were participated, 124 in control group, 200 in treatment group. According to the baseline results, there was statistical significance in the results of pelvic floor electrical physiological indexes between the treatment and control groups in postpartum 6 months and 12 months; the proportion above level III of type I and type II muscle fibers strength in the treatment group, it was from 41.5% (83/200) and 40.5% (81/200) to 76.3% (145/190) and 79.5% (151/190) in postpartum 6 weeks and postpartum 6 months, increased to 80.6% (58/72) and 80.6% (58/72) in postpartum 12 months, improved significantly comparing with the control group (P < 0.01). According to Point Aa, treatment group and control group in the postpartum 6 weeks was (-2.2 ± 0.7) versus (-2.4 ± 0.6) cm, in postpartum 12 months (- 2.5 ± 1.1) versus (- 2.7 ± 0.6) cm, the improvement in treatment group was statistically significant (P < 0.01). And the other points were not significantly different (P > 0.05). There was no significant difference in the questionnaires in quality of life and quality of sexual life (P > 0.05). CONCLUSION: Neuromuscular electrical stimulation and biofeedback therapy in the early postpartum period could obviously improve pelvic floor electrical physiological indexes, and is beneficial to prevent the pelvic floor dysfunction.
Asunto(s)
Trastornos del Suelo Pélvico/rehabilitación , Diafragma Pélvico/fisiopatología , Prolapso de Órgano Pélvico/prevención & control , Biorretroalimentación Psicológica , China , Terapia por Estimulación Eléctrica , Terapia por Ejercicio/métodos , Femenino , Humanos , Contracción Muscular , Trastornos del Suelo Pélvico/terapia , Periodo Posparto , Embarazo , Estudios Prospectivos , Calidad de Vida , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
BACKGROUND: To investigate the effects of childbirth age on maternal and infant outcomes in pregnant women. METHODS: The clinical data of 4552 singleton parturient women and their newborns treated in the Second People's Hospital of Liaocheng, China from June 2015 to June 2017 were retrospectively analyzed. They were divided into group A (<20 yr old), group B (20-<30 yr old,), group C (30-<35 yr old), group D (35-<40 yr old), group E (≥40 yr old) according to the age of the parturient women. The incidence rates of pregnancy complications and adverse pregnancy outcomes of the pregnant and parturient women and their newborns in each group were compared. RESULTS: With the increase of childbirth age, the incidence rates of pregnancy complications in pregnant women were increased gradually (P=0.028, 0.038, 0.042, 0.025, 0.012). The incidence rates of adverse pregnancy outcomes were increased gradually with the increase of childbirth age (P=0.006, 0.026, 0.010, 0.028). After correction of factors including pre-pregnancy body mass index (BMI), parity, gravidity and educational level, the incidence rate of cesarean section was reduced and the incidence rate of premature birth was increased in group A compared with those in group B. The incidence rates of cesarean section, premature birth, postpartum hemorrhage of pregnant women and the transference of newborns into NICU in group C, D and E were higher than those in group B (P=0.002, 0.019, 0.043, 0.015). CONCLUSION: Both low and high age pregnancy can increase the incidence rate of adverse pregnancy outcomes.
RESUMEN
BACKGROUND: This study aims to evaluate the short-term efficacy of concurrent chemoradiotherapy (CCRT) in primary fallopian tube carcinoma (PFTC) using magnetic resonance diffusion-weighted imaging (MR-DWI). PATIENTS AND METHODS: Total abdominal irradiation was performed for 61 PFTC patients after surgery, and paclitaxel and carboplatin were used for CCRT. According to the response evaluation criteria in solid tumors (RECIST1.1), patients were divided into a sensitive (n = 36) and a resistant group (n = 25). Pearson correlation analysis was conducted to assess the correlations of tumor regression rate with apparent diffusion coefficient (ADC)pre, ADCpost, and ∆ADCpost. The efficacy of CCRT in PFTC using MR-DWI was evaluated by ROC curve, logistic regression analysis, Kaplan-Meier survival curve, and Cox regression model. RESULTS: The ADCpre in both the sensitive and the resistant group was negatively associated with the tumor regression rate (r = -0.508), while the ADCpost (r = 0.454) and ∆ADCpost (r = 0.769) were positively associated with the tumor regression rate (all p < 0.05). Histopathological type, FIGO stage, lymphatic metastasis, tumor regression rate, ADCpre, ADCpost, and ∆ADCpost were confirmed as key factors for CCRT in PFTC (all p < 0.05). CONCLUSION: Our retrospective study demonstrates the predictive value of MR-DWI in CCRT for PFTC patients.
Asunto(s)
Quimioradioterapia/métodos , Imagen de Difusión por Resonancia Magnética/métodos , Monitoreo de Drogas/métodos , Neoplasias de las Trompas Uterinas/diagnóstico por imagen , Neoplasias de las Trompas Uterinas/terapia , Neoplasias de las Trompas Uterinas/patología , Femenino , Humanos , Persona de Mediana Edad , Reproducibilidad de los Resultados , Estudios Retrospectivos , Sensibilidad y Especificidad , Resultado del TratamientoRESUMEN
BACKGROUND: Nup88 is overexpressed in a number of types of carcinomas and is associated with myometrial invasion, but its exact expression pattern in endometrial cancer and premalignant lesions is unknown. AIMS: To evaluate the role of Nup88 in endometrial cancers and atypical endometrial hyperplasia and its clinicopathological significance. METHODS: Nup88 expression was examined by immunohistochemistry in samples from 104 endometrial cancers, 21 atypical endometrial hyperplasia lesions, and 40 normal endometria. All samples were from patients who underwent surgery at the First Hospital of Hebei Medical University (Shijiazhuang, China) between April 2006 and December 2009. Nup88 expression was compared between the groups and associations were assessed between Nup88 and clinicopathological characteristics of the subjects. RESULTS: Nup88 expression in cancer (76% of samples) and atypical hyperplasia (91%) was significantly higher compared to normal endometrium (33%, both P<0.001), but there was no significant difference between endometrial cancer and atypical hyperplasia (P=0.237). The expression of Nup88 increased significantly with increasing exposure time to estrogen (P=0.033). CONCLUSIONS: Nup88 may be related to the occurrence of endometrial cancers and premalignant lesions. Nup88 might be a useful biomarker for pre-malignant lesions and early-stage endometrial cancer.
Asunto(s)
Biomarcadores de Tumor/análisis , Hiperplasia Endometrial/patología , Neoplasias Endometriales/patología , Proteínas de Complejo Poro Nuclear/biosíntesis , Lesiones Precancerosas/patología , Adulto , Anciano , Hiperplasia Endometrial/metabolismo , Neoplasias Endometriales/metabolismo , Femenino , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Proteínas de Complejo Poro Nuclear/análisis , Lesiones Precancerosas/metabolismoRESUMEN
FXYD3 expression is upregulated in numerous cancer cell types. The present study compared the FXDY3 expression in normal endometrium, premalignant lesion and endometrial cancer tissue samples, and investigated the correlation between FXDY3 expression and clinicopathological features. FXYD3 expression was analyzed by streptavidin-peroxidase immunohistochemistry in 21 normal endometrial tissue samples, 18 atypical endometrial hyperplasia samples and 50 tissues obtained from patients diagnosed with endometrial cancer. The percentage of FXYD3-positive cell expression in the normal endometrium, atypical hyperplasia and endometrial cancer tissues samples was 0, 22, and 26%, respectively. The differences between the atypical hyperplasia and endometrial cancer groups were statistically significant when compared with the normal group (P=0.007 and P=0.037, respectively). There was no significant difference between the atypical hyperplasia and endometrial cancer groups. The percentage of FXYD3-positive cells correlated with the fertility frequency (P<0.05). In conclusion, FXYD3 is a potential biomarker for endometrial cancer, and its upregulation may be an early event in endometrial carcinoma progression. In addition, FXYD3 expression in endometrial carcinoma correlates with fertility frequency.